What was studied?
A prespecified analysis grouped FLOW participants with diabetes and chronic kidney disease by their baseline kidney function.
What did the researchers report?
Serious adverse events were less frequent with semaglutide across the reported groups. Gastrointestinal events leading to discontinuation remained more frequent than with placebo.
What are the limits?
Safety collection was selective and this analysis was descriptive. It does not establish safety outside the trial population or turn fewer serious events into an absence of adverse effects.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.